Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002835 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Lymphoma
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT00002835: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00002835 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 116 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002835, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
Interventions
- DRUG Carmustine
- BIOLOGICAL Recombinant Interferon Alfa
- BIOLOGICAL Filgrastim (G-CSF)
- BIOLOGICAL Bleomycin Sulfate (BLM)
- DRUG Cisplatin (CDDP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 1995-10-30 |
| Est. Completion | 2004-02-04 |
| Phase | Phase 3 |
What the finished NCT00002835 record still lists
NCT00002835 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which Carmustine is the first listed.
NCT00002835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002835 about?
NCT00002835 is a clinical study titled "Combination Chemotherapy in Treating Patients With Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized p...
What is the current status of trial NCT00002835?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 1995-10-30. Estimated completion is 2004-02-04.
What interventions are being tested in trial NCT00002835?
The interventions under investigation include: Carmustine (DRUG), Recombinant Interferon Alfa (BIOLOGICAL), Filgrastim (G-CSF) (BIOLOGICAL), Bleomycin Sulfate (BLM) (BIOLOGICAL), Cisplatin (CDDP) (DRUG).
Who is sponsoring clinical trial NCT00002835?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002835's enrollment target sits among peer trials
116 1643rd of 2000 higher than 357 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI